Photodynamic Therapy of Atherosclerosis Using YAG-OPO Laser and Porfimer Sodium, and Comparison With Using Argon-Dye Laser

We performed photodynamic therapy (PDT) using the Yttrium Aluminium Garnet-Optical Parametric Oscillated (YAG-OPO) laser in cases of atherosclerosis, and examined its efficacy in vivo. We also performed PDT using an Argon-dye (Ar-dye) laser with the same output, and compared the efficacies. Followin...

Full description

Saved in:
Bibliographic Details
Published inJAPANESE CIRCULATION JOURNAL Vol. 63; no. 4; pp. 288 - 295
Main Authors Amemiya, Tadashi, Nakajima, Hitoshi, Katoh, Tomitsugu, Rakue, Hiroyuki, Miyagi, Manabu, Ibukiyama, Chiharu
Format Journal Article
LanguageEnglish
Published Kyoto The Japanese Circulation Society 1999
Japanese Circulation Society
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We performed photodynamic therapy (PDT) using the Yttrium Aluminium Garnet-Optical Parametric Oscillated (YAG-OPO) laser in cases of atherosclerosis, and examined its efficacy in vivo. We also performed PDT using an Argon-dye (Ar-dye) laser with the same output, and compared the efficacies. Following balloon denudation injury of the thoracoabdominal aorta, rabbits were raised on a cholesterol diet for 16 weeks, producing atheroma in that region. At 24 h following the administration of Photofrin 5 mg/kg, PDT was performed, and animals were sacrificed at 1 day, 1 week, and 2 weeks following the procedure to examine its efficacy. This was compared with the efficacy of PDT using the Ar-dye laser. Following PDT using a YAG-OPO laser, an increase in the vessel lumen was seen due to reduction of the hypertrophic intima and media, without the appearance of inflammatory cells. This result was seen more strongly in PDT using the pulse wave YAG-OPO laser than with the continuous wave Ar-dye laser, affecting not just the intima but also the media. These data demonstrated that PDT can effectively regress atherosclerotic lesions. (Jpn Circ J 1999; 63: 288 - 295)
ISSN:0047-1828
1347-4839
DOI:10.1253/jcj.63.288